NIH chooses not to use ‘march-in rights’ in prostate drug row

The US National Institutes of Health (NIH) has decided not to exercise its “march in-rights” for the Xtandi (enzalutamide) prostate drug, which is marketed by Astellas Pharma, despite calls from politicians to license the drug in a bid to lower its price.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

US refuses to compel lower prices for Pfizer and Astellas cancer drug

23 March 2023 NIH rejects petition to use “march-in” rights to allow cheaper competition | Xtandi is “widely available” to public, federal agency says.

article

NIH COVID-19 deal broadens access for poorer nations

19 May 2022 The Medicines Patent Pool and World Health Organization’s COVID-19 Technology Access Pool have signed a deal aiming to open up new technologies to people living in poorer countries.

More features

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

NIH chooses not to use ‘march-in rights’ in prostate drug row

More on this story

Editor's picks

Editor's picks

More features